They have enough to deliver on all the planned trials even at the upper end of their estimate. They also have enough to run additional Ph2's in new indications yet to be announced. And, once the FDA has approved trials and they can narrow down Ph3 costs they also likely have enough to add to the buyback should they choose.
NEU Price at posting:
$12.59 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)